Therapy concepts for thyroid carcinoma

被引：0
作者：
Eilsberger, Friederike [1 ,4 ]
Kreissl, Michael C. [2 ]
Luster, Markus [3 ]
Pfestroff, Andreas [1 ]
机构：
[1] Univ Klinikum Marburg, Klin Nukl Med, Marburg, Germany
[2] Univ Klinikum Marburg, Abt Nukl Med, Magdeburg, Germany
[3] Univ Marburg, Nucl Med, Marburg, Germany
[4] Univ Klinikum Marburg, Klin Nukl Med, Baldingerstr 1, D-35043 Marburg, Germany
来源：
LARYNGO-RHINO-OTOLOGIE | 2023年
关键词：
thyroid cancer; Schilddrusenkarzinom; Natrium-Iodid-Symporter; CANCER; I-123;
D O I：
10.1055/a-1861-7379
中图分类号：
R76 [耳鼻咽喉科学];
学科分类号：
100213 ;
摘要：
Theranostics via the sodium iodide symporter (NIS) offer a unique option in differentiated thyroid carcinoma. The diagnostic and therapeutic nuclides have similar uptake and kinetics, making the NIS the most important theranostic target in this disease. Radioiodine refractory thyroid carcinomas (RRTC) are characterised by reduced/absent NIS expression, thus eliminating this structure as a theranostic target. Also due to limited therapeutic options, there are approaches to generate new theranostic targets in RRTC, via the expression of somatostatin receptors (SSTR) or the prostate-specific membrane antigen (PSMA), but the current evidence does not yet allow a final evaluation of the prospects of success.
引用
收藏
页码：488 / 495
页数：8
相关论文
共 66 条
  • [1] Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies
    Aashiq, Mohamed
    Silverman, Deborah A.
    Na'ara, Shorook
    Takahashi, Hideaki
    Amit, Moran
    [J]. CANCERS, 2019, 11 (09)
  • [2] Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity
    Barinka, C
    Sacha, P
    Sklenar, J
    Man, P
    Bezouska, K
    Slusher, BS
    Konvalinka, J
    [J]. PROTEIN SCIENCE, 2004, 13 (06) : 1627 - 1635
  • [3] Radioiodine and thyroid disease: The beginning
    Becker, DV
    Sawin, CT
    [J]. SEMINARS IN NUCLEAR MEDICINE, 1996, 26 (03) : 155 - 164
  • [4] Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls
    Beukhof, Carolien M.
    Brabander, Tessa
    van Nederveen, Francien H.
    van Velthuysen, Marie-Louise F.
    de Rijke, Yolanda B.
    Hofland, Leo J.
    Franssen, Gaston J. H.
    Froberg, Lideke A. C.
    Kam, Boen L. R.
    Visser, W. Edward
    de Herder, Wouter W.
    Peeters, Robin P.
    [J]. BMC CANCER, 2019, 19 (1)
  • [5] 68Ga-DOTATOC PET/CT in Patients with Iodine- and 18F-FDG-Negative Differentiated Thyroid Carcinoma and Elevated Serum Thyroglobulin
    Binse, Ina
    Poeppel, Thorsten D.
    Ruhlmann, Marcus
    Ezziddin, Samer
    Goerges, Rainer
    Sabet, Amir
    Beiderwellen, Karsten
    Bockisch, Andreas
    Rosenbaum-Krumme, Sandra J.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (10) : 1512 - 1517
  • [6] Bravo PE, 2013, INT J CLIN EXP MED, V6, P320
  • [7] Budiawan H, 2014, AM J NUCL MED MOLEC, V4, P39
  • [8] Thyroid cancer
    Cabanillas, Maria E.
    McFadden, David G.
    Durante, Cosimo
    [J]. LANCET, 2016, 388 (10061) : 2783 - 2795
  • [9] Thyroid hormone biosynthesis and release
    Carvalho, Denise P.
    Dupuy, Corinne
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2017, 458 (0C) : 6 - 15
  • [10] Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation
    Chakravarty, Debyani
    Santos, Elmer
    Ryder, Mabel
    Knauf, Jeffrey A.
    Liao, Xiao-Hui
    West, Brian L.
    Bollag, Gideon
    Kolesnick, Richard
    Thin, Tin Htwe
    Rosen, Neal
    Zanzonico, Pat
    Larson, Steven M.
    Refetoff, Samuel
    Ghossein, Ronald
    Fagin, James A.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (12) : 4700 - 4711
1234567